{"id":"W4414886615","doi":"10.1038/s41591-025-03961-8","title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","year":2025,"lang":"en","type":"article","venue":"Nature Medicine","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency; University of Calgary","funders":"National Cancer Institute; National Institute for Health and Care Research","keywords":"Abiraterone acetate; Hazard ratio; Prednisone; Prostate cancer; Clinical endpoint; Placebo; Confidence interval; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001297532,0.0003530337,0.00156705,0.0003961945,0.0002067672,0.00003444693,0.00007648078,0.0001887478,0.00005022616],"category_scores_gemma":[0.0008229135,0.0002141152,0.0001534896,0.0005183047,0.0006458444,0.00008939709,0.00003961464,0.0005942783,0.000001831213],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002840002,"about_ca_system_score_gemma":0.0007528333,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001787766,"about_ca_topic_score_gemma":0.00006829213,"domain_scores_codex":[0.9975553,0.0001923697,0.000647692,0.0005832483,0.0005254593,0.0004958862],"domain_scores_gemma":[0.9980463,0.0006983165,0.000198517,0.000273062,0.0005581129,0.0002256298],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9644028,0.0004114469,0.00002478375,0.0007812102,0.001344069,0.0001197933,0.002476935,0.00001151537,0.01004813,0.0009224071,0.005071018,0.01438589],"study_design_scores_gemma":[0.9728249,0.002913532,0.00006619014,0.0008496578,0.002206407,0.00002951261,0.0006860542,0.002845129,0.01250196,0.0005165921,0.004381862,0.0001781609],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8785558,0.05196757,0.002028795,0.04403423,0.001714969,0.01994857,0.0003357886,0.0001300716,0.001284158],"genre_scores_gemma":[0.9786429,0.003931236,0.0008120538,0.001505684,0.0004458218,0.002328709,0.0005509438,0.00003745664,0.01174518],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1000871,"threshold_uncertainty_score":0.8731364,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02724839226654019,"score_gpt":0.4052032772086769,"score_spread":0.3779548849421367,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}